Back Stocks profile

Stock analysis tool for investors

Aarti Drugs Ltd.

NSE: AARTIDRUGS | BSE:524348

₹484.70 0.65 (0.13%) 1D

Pharmaceuticals & Biotechnology

Open free demat account View detailed Technical chart

Open an Account with Bigul

Performance Online share trading app

Today’s low

480.20

Today’s High

491.70

52W low

431.00

52W High

635.00

Open Price

486.60

Prev. Close

484.0500

Volume

69203.00

Value

33542694.10

Fundamentals Open free demat account

Market Cap

4423.90

Price to Earnings

29.10

Price to Book Value

3.50

Dividend Yield

0.20

PE to Growth

-1.90

Op Revenue TTM

2379.60

Net Profit TTM

152.23

Cash From Operating Activity

358.92

Return on Equity %

13.37

EMA & SMA

Online share trading app Open free demat account

Bullish Moving Averages

2

Bearish Moving Averages

14

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

30 Oct, 2024

47.1

Week

41.3

Month

46.4

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

485.52

PIVOT

First Resistance

490.88

Second Resistance

497.07

Third Resistance

502.43

First Support

479.33

Second Support

473.97

Third Support

467.78

Relative Strength Index

33.15

Money Flow Index

26.63

MACD

-11.51

MACD Signal

-10.7

Average True Range

12.64

Average Directional Index

22.93

Rate of Change (21)

-5.55

Rate of Change (125)

-3.21

Day Commodity Channel Index

-80.3

William

-61.53

BETA

1 Month

0.77

3 Month

0.72

1 Year

0.66

3 Year

0.43

PRICE CHANGE ANALYSIS

-0.8%

1 Week

Low

High

466.1

492

-5.76%

1 Month

Low

High

466.1

529

-3.69%

3 Months

Low

High

466.1

635

-4.41%

6 Months

Low

High

451.05

635

2.9%

1 Year

Low

High

431.05

635

Bigul
25 Oct 2024

Here's why Aarti Drugs shares fell 4% on October 25, more details here

The fall in Aarti Drugs share price came after the company reported a weak set of September quarter (Q2FY25) earnings.
Bigul
25 Oct 2024

H1FY25 & Q2FY25 Result Announced for Aarti Drugs Ltd.

Pharmaceuticals company Aarti Drugs announced H1FY25 & Q2FY25 results Q2FY25 Standalone Financial Highlights: Revenue stood at Rs 543.1 crore as against Rs 577.5 crore, down by 6% YoY. Standalone business contributed ~89% to the consolidated revenue for the quarter. ~66% of the revenues came from the domestic market and ~34% from the exports market. Within the API business, the antibiotic therapeutic category contributed ~40%, anti-diabetic ~18%, antiprotozoal ~17%, anti-inflammatory ~10%, antifungal ~10% and the rest contributed ~4% to total API sales Q2FY25 Consolidated Financial Highlights: Revenue stood at Rs 599.8 crore as against Rs 642.2 crore, a decline of 7% YoY. This is on account of lower realizations stemming from negative rate variance and subdued market demand in the API business. EBITDA stood at Rs 68.5 crore as against Rs 77.1 crore, a decline of 11% YoY. EBITDA Margin (%) stood at 11.5%. PAT stood at Rs 35.0 crore as against Rs 39.6 crore, a decline of 12% YoY. PAT Margin (%) stood at 5.8% H1FY25 Consolidated Financial Highlights: Revenue stood at Rs 1,156.3 crore as against Rs 1,303.9 crore, a decline of 11% YoY. EBITDA stood at Rs 134.6 crore as against Rs 161.8 crore, a decline of 17% YoY. EBITDA Margin (%) stood at 11.7%. PAT stood at Rs 68.2 crore as against Rs 87.6 crore, a decline of 22% YoY. PAT Margin (%) stood at 5.9% Adhish Patil, CFO & COO, of Aarti Drugs said: “During Q2FY25, we have seen a drop in revenues and profitability on a year-on-year basis mainly due to lower realizations stemming from negative rate variance and subdued market demand in the API business. The volumes have remained flattish on a YoY basis whereas we have seen a growth of 10% from the last quarter. Since Q1, the prices have stabilized, and volumes have grown which has led to a growth of 8% in revenues on a QoQ basis. We expect pricing to improve going ahead. Formulation segment revenue stood at Rs 65.6 crore for the quarter, with exports contribution of ~53%. In H1FY25 revenue stood at Rs 136.6 crore. The greenfield project at Sayakha, Gujarat for Speciality Chemicals is expected to commence in this quarter. With this, the operating leverage is expected to kick in from the second half of the year with improved capacity utilization. The production of Salicylic Acid has commenced and currently we are producing 100 tonnes per month. There have been certain teething issues, and we expect to ramp up the production to 300+ tonnes by end of October’24. In total we will have sequential ramp up of capacity to 1,800 tonnesthroughout FY25 & FY26. During H1 FY25, the Company has incurred Capex of ~Rs 90 crore mainly towards capacity expansion, backward integration and new product launches. We anticipate a total Capex of ~Rs 200 crore for the full year. This Capex would we mainly through internal accruals and partly through term loans. The Pharma API manufacturing industry is constantly evolving, and we are committed to staying ahead of the curve. We continue to expand our capabilities and enhance our offerings to meet the ever-changing needs of our customeRs We also plan to invest in new technologies and equipment that will help us streamline our processes and improve efficiency.” Result PDF
Bigul
24 Oct 2024

AARTI DRUGS LTD. - 524348 - Financial Results For The Quarter And Half Year Ended September 30, 2024

Financial Results for the quarter and half year ended September 30, 2024
See all News

FAQs

Investment Platform in India

The latest market price of Aarti Drugs Ltd. on NSE was Rs. 484.70 as of today.

The opening share price of Aarti Drugs Ltd. was Rs. 486.60 as of today.

The 52-week high share price of Aarti Drugs Ltd. was Rs. 635.00.

The 52 week low share price of Aarti Drugs Ltd. was Rs. 431.00.

Please find Corporate actions section for more details.

The PE ratio of Aarti Drugs Ltd. is -1.90. Please refer to the Fundamentals section for further details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Aarti Drugs Ltd. was on 2024-02-06 for Rs. 1 per share. According to today’s share price, the dividend yield of Aarti Drugs Ltd. stands at 0.20. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Aarti Drugs Ltd. was as of 2020-09-30. The bonus ratio declared in this issue was 3:1. Please refer to the Corporate Actions section for further details.

Please find Corporate actions section for more details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Aarti Drugs Ltd..

Investment Platform in India
Close

Let's Open Free Demat Account